Bayer Healthcare LLC

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Bayer Intellectual Property Gmbh

Compugen Ltd. Corporation

Uwe Gritzan

Frank Dittmer

Michael Strerath

Christian Votsmeier

Dorian Schönfeld

Julian Marius Glück

Terry Hermiston

Simon Holton

Christoph Freiberg

Sandra Berndt

Mark Trautwein

Ye Jin

John E Murphy

Sven Golfier

Jörg Willuda

Timothy Myles

Yingzi Ge

Philip Beckhove

Eva-Maria Gutierrez

Jessica Pinkert

Beatrix Stelte-Ludwig

Jan Tebbe

Ernst Weber

Wayne Coco

Nikolaus Pawlowski

Ulrich Haupts

Susanne Steinig

Peter Scholz

Andreas Scheidig

Peter Kretschmer

Sabine Hoff

Katharina Filarsky

Simone Brückner

Lilley Leong

Su-Yi Tseng

Wiebke Maria Nadler

Helge Roider

Hanna Plittersdorf

Klaus Pellengahr

Kerstin Baral

Kornelia Kirchner

Chandra Patel

Patrick Jones

Hans-Georg Lerchen

Ofer Levy

Anne-Sophie Rebstock

Yolanda Cancho Grande

John J Hunter

Simone Greven

Spencer Liang

Sven Wittrock

Lisa Dietz

Christoph Mahlert

Ilan Vaknin

Lars Röse

Stephan Märsch

Oliver Von Ahsen

Stefanie Hammer

Matyas Gorjanacz

Philipp Ellinger

Simone Brueckner

Jenny Fitting

Phaik Lyn Oh

Pedro Paz

Pascale Buchmann

Christian Bertling

Andrew Pow

Julia Hütter

Wayne M Coco

Jan Tebe

Gutierrez Eva-Maria

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human,and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Methods of treatment using CCR8 antibodies

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human andCEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-CEACAM6 antibodies and uses thereof

The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

ILDR2 antagonists and combinations thereof

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

CCR8 antibodies for therapeutic applications

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.

Variant factor VIII polypeptides and methods of their production and use

This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin &#x3b2; complexed with heparin and/or heparin-like structure (AT&#x3b2;H). These AT&#x3b2;H binding proteins can block the anti-coagulant activity of AT&#x3b2; to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

Monoclonal antibodies against antithrombin beta

Monoclonal antibodies against antithrombin &#x3b2;

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

Growing community of inventors

Cologne, Germany

Uwe Gritzan